BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.

Michalis Liontos Eleni ZografosPanagiotis ZoumpourlisAngeliki Andrikopoulou Anna Svarna Oraianthi FisteElena KunadisAlkistis Maria PapatheodoridiMaria KaparelouKonstantinos KoutsoukosNikoloas ThomakosDimitrios HaidopoulosAlexandros RodolakisMeletios- Athanasios DimopoulosFlora Zagouri

Published in: Current oncology (Toronto, Ont.) (2021)

carriers with mutations in different locations of the genes show no significant difference in survival outcomes, in terms of PFS and OS, suggesting the potential effect of other genetic abnormalities and co-contributing risk factors.

Keyphrases

risk factors
end stage renal disease
genome wide
ejection fraction
newly diagnosed
chronic kidney disease
gene expression
risk assessment
climate change
human health
transcription factor